Tom Lynch out­lines his come­back strat­e­gy for Bris­tol-My­ers’ bad­ly bruised R&D or­ga­ni­za­tion

Thomas Lynch

When Tom Lynch took the top R&D job at Bris­tol-My­ers Squibb, he got one of the best — and at the same time, one of the hard­est — jobs in biotech.

It was one of the best be­cause Bris­tol-My­ers built what is wide­ly con­sid­ered one of the most in­no­v­a­tive re­search groups for a bio­phar­ma of its size, in a heavy­weight class not known for home­made break­throughs. It was one of the hard­est be­cause the group had just de­railed, giv­ing up its first-place po­si­tion in im­muno-on­col­o­gy in a hard fall on a mis­guid­ed late-stage ef­fort on lung can­cer.

That’s how Lynch end­ed up with the job.

Dur­ing yes­ter­day’s Q1 call with an­a­lysts, Lynch — who made an un­usu­al move from the board to head of R&D — out­lined his strat­e­gy for what comes next. How can Bris­tol-My­ers re­trieve its lead po­si­tion?

As Lynch not­ed to a group that in­clud­ed some ex­pe­ri­enced skep­tics, his board­room po­si­tion gave him a bird’s eye view of the com­pa­ny’s op­er­a­tions. For a first in­ter­view with an­a­lysts, he pro­vid­ed an im­pres­sive, de­tailed strat­e­gy out­line, rec­og­niz­ing the weak­ness­es in Bris­tol-My­ers’ I/O ef­forts and of­fer­ing ways to deal with those weak­ness­es in the clin­ic.

Lynch’s game plan cen­ters on the com­pa­ny’s work on next-gen com­bos, look­ing to build on Op­di­vo (PD-1) and Yer­voy (CT­LA-4) — with all its faults — with new com­bos and less tox­ic al­ter­na­tives now in the clin­ic.

In Lynch’s words, here’s the strat­e­gy:

— (F)irst, ac­cel­er­at­ing the de­liv­ery of our next wave of I-O as­sets like IDO, which we re­cent­ly pre­sent­ed da­ta on at AACR. We’ll al­so be pre­sent­ing ear­ly re­sults for LAG-3, GITR, and the In­cyte IDO at AS­CO this year.

— Sec­ond, un­der­stand­ing the bi­ol­o­gy of I-O re­sis­tance, both in­trin­sic re­sis­tance and ac­quired, and bring­ing a laser-like fo­cus to over­com­ing this. We will fo­cus on ex­pand­ing in­to tu­mor types where I-O hasn’t had a broad im­pact yet, tu­mors like breast can­cer, col­orec­tal can­cer, and prostate can­cer. We will use our next-wave as­sets to cre­ate op­tions for pa­tients who progress on their ini­tial I-O ther­a­py.

— Third, we will con­tin­ue to de­vel­op com­bi­na­tion reg­i­mens, in­clud­ing I-O/I-O com­bi­na­tions, I-O/tar­get­ed com­bi­na­tions, and I-O/chemother­a­py com­bi­na­tions where these make sense.

— And fourth, we will ac­cel­er­ate the de­vel­op­ment of our most promis­ing as­sets in the car­dio­vas­cu­lar, im­muno-sci­ence, and fi­bro­sis pipeline. As [CEO] Gio­van­ni [Caforio] men­tioned, we re­cent­ly pre­sent­ed promis­ing Phase II da­ta on our FGF21 as­set in pa­tients with NASH at the In­ter­na­tion­al Liv­er Con­gress. The re­sults showed an im­prove­ment across mul­ti­ple as­pects of NASH, in­clud­ing a sig­nif­i­cant re­duc­tion in liv­er fat ver­sus place­bo.

He fol­lowed up by cit­ing an ex­pand­ed re­la­tion­ship with Cy­tomX to build a less tox­ic CT­LA-4, a move that could even­tu­al­ly have ma­jor im­pli­ca­tions for con­tenders like As­traZeneca, and all the big ri­vals cur­rent­ly in the mar­ket, from Mer­ck to Roche and Pfiz­er/Mer­ck KGaA. IDO com­bi­na­tions will play a role here as well.

Ge­off Meacham at Bar­clays ob­serves that it seems that the biggest op­por­tu­ni­ty is in “cold tu­mors, breast, ovar­i­an, colon, et cetera. To fol­low up on the ear­li­er com­ment, CT­LA-4 com­bos, do you guys feel, at this point, CT­LA-4 com­bos plus a PD-L1 is go­ing to be a com­po­nent of that?”


So we think we have mul­ti­ple op­por­tu­ni­ties to look at com­bi­na­tions of I-O/I-O agents in these cold tu­mors. We pre­sent­ed da­ta with our IDO as­set, as you men­tioned, and we al­so will be pre­sent­ing ini­tial da­ta at AS­CO this year with our GITR com­pound, which could be the type of agent that might play a role in the cold tu­mor space.

Tim An­der­son at Bern­stein al­so ze­roed in on grow­ing ques­tions about the fu­ture of PD-1, CT­LA-4 com­bos. “A bear’s point of view could say that this fore­tells prob­lems with Yer­voy and Op­di­vo, specif­i­cal­ly in front-line lung.”


I think the first is that again, just em­pha­siz­ing how com­plex and dif­fi­cult a dis­ease lung can­cer is to treat, it’s high­ly un­like­ly that there’s go­ing to be one ap­proach that’s go­ing to fit every pa­tient who presents in first-line. We be­lieve strong­ly that Yer­voy/Op­di­vo is cer­tain­ly one of the op­tions that needs to be pur­sued and de­vel­oped, and we’re look­ing at that in first-line lung can­cer. And we’re al­so look­ing at it in the set­ting of what ap­pro­pri­ate bio­mark­ers might be im­por­tant in eval­u­at­ing the po­ten­tial for this com­bi­na­tion and for re­al­ly all of our drugs in first-line lung can­cer.

Fi­nal­ly, on new R&D in­vest­ments:

“(W)e’ve got to ex­e­cute our pipeline. We’ve got to de­vel­op our next-gen­er­a­tion drugs. And to do that, we’re go­ing to need to in­vest in tu­mor bi­ol­o­gy and trans­la­tion­al med­i­cine as well as da­ta and an­a­lyt­ics.”

So there’s the plan. Tak­ing over at R&D now is like jump­ing on a rolling truck at Bris­tol-My­ers, which spent $5 bil­lion on re­search last year. You can grab the wheel, but then you have to man­age the mo­men­tum. That won’t be easy.

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

Let the long battle for biosimilars in the cancer space begin.

Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab-anns). While the biotech had been fielding biosimilars in Europe, this marks their first foray in the US — and the first oncology biosimilars in the country.

Seer adds ex-FDA chief Mark Mc­Clel­lan to the board; Her­cules Cap­i­tal makes it of­fi­cial for new CEO Scott Bluestein

→ On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its board. “Mark’s deep understanding of the health care ecosystem and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market,” said Seer chief and founder Omid Farokhzad in a statement.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Daniel O'Day

No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

Gilead CEO Daniel O’Day’s new task hunting up a CSO for the company isn’t stopping the industry’s dominant antiviral player from doing pipeline deals.

The big biotech today snapped up 3 preclinical antiviral programs from pharma giant Novartis, with drugs promising to treat human rhinovirus, influenza and herpes viruses. We don’t know what the upfront is, but the back end has $291 million in milestones baked in.

Vas Narasimhan, AP Images

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly to suc­ceed?

Novartis CEO Vas Narasimhan is living in the sweet spot right now.

The numbers are running a bit better than expected, the pipeline — which he assembled as development chief — is performing and the stock popped more than 4% on Thursday as the executive team ran through their assessment of Q2 performance.

Year-to-date the stock is up 28%, so the investors will be beaming. Anyone looking for chinks in their armor — and there are plenty giving it a shot — right now focus on payer acceptance of their $2.1 million gene therapy Zolgensma, where it’s early days. And CAR-T continues to underperform, but Novartis doesn’t appear to be suffering from it.

So what could go wrong?

Actually, not much. But Tim Anderson at Wolfe pressed Narasimhan and his development chief John Tsai to pick which of two looming Phase III readouts with blockbuster implication had the better odds of success.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.